OncoBio Consolider Network

Understanding the Cancer Biology

+ 34 912 246 900
oncobio@oncobio.org

Ministerio de Economía y Competitividad

Research Areas

Research projects within the OncoBIO initiative are divided in four major research programmes (I-IV) and two horizontal programmes (A-B) focused to implement and share cutting-edge genomic and in vivo technologies.

Programme I

The molecular Basis of Cancer.


In this program, the OncoBIO team will join efforts and expertise to discover new components, pathways, and mechanisms that will provide new insights into the molecular basis of cancer.
The specific objectives of this programme are:
  • Identification of cancer-relevant regulators of K-Ras and H-Ras tumorigenesis.
  • Identification of regulators of the epithelial-mesechymal transition.
  • Identification of mechanisms involved in the control of the cell cycle and its checkpoints.
  • Characterization of the novel functions of the main tumour suppression pathways.
  • Identification of new genes involved in the response to DNA damage.
  • Impact of the telomere biology on cancer.

Programme II

Stem Cells and Cancer.


A fundamental issue in cancer research is the identification of cells capable of initiating and sustaining the outgrowth of tumors, the so called cancer stem cells (CSCs).
The specific milestones of this programme are:
  • Identification of stem cell niches in different mouse and human tissues and tumor types using the "telomapping" technique.
  • Generation of new mouse models targeting cancer genes to stem cell compartments.
  • Functional analysis of the genetic programmes that characterize normal vs. cancer stem cells, in particular those driven by Wnt signaling. Characterization of the relationship between process of epithelial-to-mesenchymal transition and the migration of cancer stem cells during the metastatic dissemination.
  • Analysis of the role of DNA repair genes, genome stability and cell cycle regulators in normal and cancer stem cells.
  • Mapping stem cell markers in normal and tumoral tissues.

Programme III

Tumor Microenviroment.


A critical issue in tumor development is the complex tumor-microenvironment interaction which is now considered as a key element for understanding and treating malignant tumors.
The specific objectives of this programme are the following:
  • Setup experimental systems to explore the relevance of genetic alterations in stromal cells during cancer progression.
  • Determine the role of Snail and bHLH factors in EMT and epithelial plasticity during tumor progression.
  • Setup experimental systems to analyze the role of inflammation in colon, prostate and pancreas cancer.
  • Generate genetically modified animals with alterations in specific proteases involved in tumor microenvironment dynamics.
  • Define the effects of alterations in Snail, LOXL2/3, ephrin and protease signaling on tumor invasion and metastasis using genetically-modified animals.

Programme IV

Diagnostic and Therapeutic Applications.


This programme had two general aims derived from the application of the knowledge on fundamental mechanisms involved in cancer generated by the team members:
  1. development of strategies to improve cancer diagnosis and classification and
  2. identification and validation of targets that may be therapeutically useful.
The specific goals of this programme are:
  • Identification of novel biomarkers predictive of outcome and response to therapy in gynecological, breast, bladder, prostate, and colon cancer.
  • Identification of interacting pathways to improve tumor molecular classification: from mouse to human cancer.
  • Validation, in human tumors, of biomarkers identified through the studies of murine genetic models of cancer (Snail1, Snail2, E47, LOXL2).
  • Validation, in human tumors, of CSC signatures identified through the studies of murine genetic models of cancer (colon, breast, lung, and head and neck).
  • Identification of novel cancer targets through the use of mouse models and pilot studies of suitability as human cancer targets.
  • Use of protease-deficient mice as animal models for validating anti-tumoral or antimetastatic strategies.

About us

The OncoBIO Consolider Network was constituted in December 10th 2007 with the main goal of a better understand of the Cancer Biology.

This coordinated project will provide critical information for the development of new strategic opportunities aimed at improving those diagnostic and therapeutic approaches currently used to treat cancer patients.

Upcoming Events

19 October 2015

Send us your CV

If you are interested in working with us, send your CV indicating the position you want to apply to the e-mail oncobio@oncobio.org

Latest Publications